Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

JP Morgan Upgrades Sepracor to 'Overweight'

JP Morgan upgraded Sepracor (SEPR) to overweight from underweight.

The drug company plans to submit a new drug application for Estorra, its insomnia treatment, by mid-February. Analyst Corey Davis thinks the news means the FDA has seen all of the data, and has at least preliminarily agreed that the data package is complete. Given the market's skepticism, Davis says he believes this is a positive outcome of a binary event, and is a step towards increasing investors' confidence.

Davis notes Sepracor's current competitors, Ambien & Sonata, should earn $1.2 billion in 2002. From the data he has seen, Davis says he thinks Estorra has the potential to be a best-in-class drug. He says the next competitor, Neurocrine Bioscience's Indiplon, is one to two years behind. He also thinks Sepracor's stock will now start to get credit for its deep pipeline. Davis has a $13 target.

blog comments powered by Disqus